Astute Medical will receive $30 million from funding partner CRG. The funds will go towards commercialization of the diagnostic NephroCheck Test System for acute kidney injury, and an additional $10 million will become available to Astute when it achieves certain preset revenue milestones. The FDA recently cleared the system and give its stamp of approval for Astute to start selling the product to the public. Release